135 related articles for article (PubMed ID: 20146241)
1. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src.
Sakuma Y; Takeuchi T; Nakamura Y; Yoshihara M; Matsukuma S; Nakayama H; Ohgane N; Yokose T; Kameda Y; Tsuchiya E; Miyagi Y
J Pathol; 2010 Apr; 220(5):574-85. PubMed ID: 20146241
[TBL] [Abstract][Full Text] [Related]
2. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.
Uekita T; Jia L; Narisawa-Saito M; Yokota J; Kiyono T; Sakai R
Mol Cell Biol; 2007 Nov; 27(21):7649-60. PubMed ID: 17785447
[TBL] [Abstract][Full Text] [Related]
3. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
Sakuma Y; Tsunezumi J; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
Oncol Rep; 2011 Mar; 25(3):661-7. PubMed ID: 21206976
[TBL] [Abstract][Full Text] [Related]
4. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis.
Wei L; Yang Y; Zhang X; Yu Q
Oncogene; 2004 Dec; 23(56):9052-61. PubMed ID: 15489898
[TBL] [Abstract][Full Text] [Related]
5. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
6. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Nakayama H; Yokose T; Kameda Y; Koizume S; Miyagi Y
Lab Invest; 2012 Mar; 92(3):371-83. PubMed ID: 22157722
[TBL] [Abstract][Full Text] [Related]
7. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
8. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
9. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
10. Src family kinases and HER2 interactions in human breast cancer cell growth and survival.
Belsches-Jablonski AP; Biscardi JS; Peavy DR; Tice DA; Romney DA; Parsons SJ
Oncogene; 2001 Mar; 20(12):1465-75. PubMed ID: 11313890
[TBL] [Abstract][Full Text] [Related]
11. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).
Frankel A; Rosen K; Filmus J; Kerbel RS
Cancer Res; 2001 Jun; 61(12):4837-41. PubMed ID: 11406560
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of GLC-82 lung carcinoma cell aggregation in suspension culture to the activation of protein kinases FAK, AKT, ERK, and SRC].
Fang Y; Zhang X; Zhang JR; Jiang WQ
Ai Zheng; 2005 Oct; 24(10):1206-12. PubMed ID: 16219134
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
14. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
15. Src activation regulates anoikis in human colon tumor cell lines.
Windham TC; Parikh NU; Siwak DR; Summy JM; McConkey DJ; Kraker AJ; Gallick GE
Oncogene; 2002 Nov; 21(51):7797-807. PubMed ID: 12420216
[TBL] [Abstract][Full Text] [Related]
16. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
17. Primary human colonic epithelial cells are transiently protected from anoikis by a Src-dependent mechanism.
Hofmann C; Lippert E; Falk W; Schölmerich J; Rogler G; Obermeier F
Biochem Biophys Res Commun; 2009 Dec; 390(3):908-14. PubMed ID: 19852943
[TBL] [Abstract][Full Text] [Related]
18. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC
J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110
[TBL] [Abstract][Full Text] [Related]
20. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
Zhang J; Kalyankrishna S; Wislez M; Thilaganathan N; Saigal B; Wei W; Ma L; Wistuba II; Johnson FM; Kurie JM
Am J Pathol; 2007 Jan; 170(1):366-76. PubMed ID: 17200208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
